The death of key retinal cells, including photoreceptors, is the root cause of vision loss and the leading cause of blindness. ONL is leveraging its breakthrough vision protection technology to develop novel treatments for a range of serious, vision-threatening retinal diseases and conditions.
While its initial drug development efforts are focused on retinal detachment, a condition for which the company has been granted orphan drug designation, preclinical in vivo data, along with a growing body of literature, support potential application in age-related macular degeneration (AMD) and other chronic retinal diseases.
Note: 20/20 is considered normal vision. 20/40 is the minimum legal standard for driving in most states and jurisdictions. An individual with 20/40 vision must be only 20 feet away to see an object that a person with normal vision can see from 40 feet away.
Combined, the estimated market for the initial indications that ONL plans to target is >$12 billion globally.